Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Convertible Debt: 2014-2018

Historic Convertible Debt for Viking Therapeutics (VKTX) over the last 2 years, with Mar 2018 value amounting to $1.5 million.

  • Viking Therapeutics' Convertible Debt fell 59.60% to $1.5 million in Q1 2018 from the same period last year, while for Mar 2018 it was $1.5 million, marking a year-over-year decrease of 59.60%. This contributed to the annual value of $1.5 million for FY2017, which is negligibly% changed negligibly from last year.
  • Per Viking Therapeutics' latest filing, its Convertible Debt stood at $1.5 million for Q1 2018, which was down 0.00% from $1.5 million recorded in Q4 2017.
  • Over the past 5 years, Viking Therapeutics' Convertible Debt peaked at $3.7 million during Q1 2017, and registered a low of $1.3 million during Q4 2014.
  • Moreover, its 3-year median value for Convertible Debt was $1.5 million (2018), whereas its average is $1.9 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first surged by 119.57% in 2016, then plummeted by 59.60% in 2018.
  • Viking Therapeutics' Convertible Debt (Quarterly) stood at $1.3 million in 2014, then surged by 70.20% to $2.2 million in 2015, then slumped by 30.28% to $1.5 million in 2016, then remained steady at $1.5 million in 2017, then tumbled by 59.60% to $1.5 million in 2018.
  • Its Convertible Debt was $1.5 million in Q1 2018, compared to $1.5 million in Q4 2017 and $1.5 million in Q3 2017.